Cyclooxygenase-2 expression as a prognostic factor in pediatric classical Hodgkin lymphoma

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Cyclooxygenase-2 (COX-2) is implicated in tumor development, angiogenesis, and proliferation.
• Elevated COX-2 expression is observed in many cancers and often correlates with a poor prognosis.
• The prognostic significance of COX-2 in pediatric classical Hodgkin lymphoma (CHL) remains to be fully elucidated.

Purpose of the Study:

• To investigate the prognostic value of COX-2 expression in Reed-Sternberg (RS) cells of pediatric classical Hodgkin lymphoma (CHL) patients.
• To correlate COX-2 immunostaining with clinical variables and patient outcomes.

Main Methods:

• Retrospective analysis of 127 pediatric CHL patients treated between January 2005 and June 2013.
• Immunohistochemical assessment of COX-2 expression in RS cells.
• Correlation of COX-2 status with overall survival (OS) and progression-free survival (PFS) using univariate and multivariate analyses.

Main Results:

• COX-2 was expressed in 38.6% of RS cells.
• No significant association was found between COX-2 positivity and overall 5-year OS or PFS in the entire cohort.
• However, COX-2 positivity was associated with significantly lower 5-year OS in high-risk patients and lower 5-year PFS in patients with B symptoms or bulky disease.
• Radiotherapy improved survival in both COX-2 positive and negative groups, with a numerically greater benefit in the COX-2 positive group.

Conclusions:

• COX-2 expression in pediatric CHL shows a trend towards being a poor prognostic factor but does not offer independent prognostic information.
• Further large-scale studies are warranted to confirm COX-2's prognostic role and explore its potential as a therapeutic target in CHL.